B. Haynes, P. Gilbert, M. Mcelrath, S. Zolla-pazner, G. Tomaras et al., Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial, New England Journal of Medicine, vol.366, issue.14, pp.1275-1286, 2012.
DOI : 10.1056/NEJMoa1113425

M. Robb, S. Rerks-ngarm, S. Nitayaphan, P. Pitisuttithum, J. Kaewkungwal et al., Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144, The Lancet Infectious Diseases, vol.12, issue.7, pp.531-537, 2012.
DOI : 10.1016/S1473-3099(12)70088-9

R. Steinman, Decisions About Dendritic Cells: Past, Present, and Future, Annual Review of Immunology, vol.30, issue.1, pp.1-22, 2012.
DOI : 10.1146/annurev-immunol-100311-102839

B. Flynn, K. Kastenmuller, U. Wille-reece, G. Tomaras, M. Alam et al., Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates, Proceedings of the National Academy of Sciences, vol.108, issue.17, pp.7131-7136, 2011.
DOI : 10.1073/pnas.1103869108

D. Li, R. G. Flamar, A. Duluc, D. Dullaers, M. et al., T cells, The Journal of Experimental Medicine, vol.3, issue.1, pp.109-121, 2012.
DOI : 10.4049/jimmunol.167.10.5767
URL : https://hal.archives-ouvertes.fr/hal-00612703

H. Joo, D. Li, M. Dullaers, T. Kim, D. Duluc et al., C-Type Lectin-like Receptor LOX-1 Promotes Dendritic Cell-Mediated Class-Switched B Cell Responses, Immunity, vol.41, issue.4, pp.592-604, 2014.
DOI : 10.1016/j.immuni.2014.09.009
URL : http://doi.org/10.1016/j.immuni.2014.09.009

B. Perdiguero, C. Gomez, V. Cepeda, L. Sanchez-sampedro, and J. Garcia-arriaza, ABSTRACT, Journal of Virology, vol.89, issue.2, pp.970-988, 2015.
DOI : 10.1128/JVI.02469-14

P. Pitisuttithum, P. Gilbert, M. Gurwith, W. Heyward, M. Martin et al., Randomized, Double???Blind, Placebo???Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV???1 Vaccine among Injection Drug Users in Bangkok, Thailand, The Journal of Infectious Diseases, vol.194, issue.12, pp.1661-1671, 2006.
DOI : 10.1086/508748

S. Rerks-ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu et al., Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand, New England Journal of Medicine, vol.361, issue.23, pp.2209-2220, 2009.
DOI : 10.1056/NEJMoa0908492

S. Zolla-pazner, A. Decamp, P. Gilbert, C. Williams, N. Yates et al., Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection, PLoS ONE, vol.188, issue.2, p.24504509, 2014.
DOI : 10.1371/journal.pone.0087572.s007

S. Zolla-pazner, P. Edlefsen, R. M. Kong, X. Decamp, A. Gottardo et al., Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses, EBioMedicine, vol.1, issue.1, pp.37-45, 2014.
DOI : 10.1016/j.ebiom.2014.10.022

N. Yates, H. Liao, Y. Fong, A. Decamp, N. Vandergrift et al., Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination, Science Translational Medicine, vol.6, issue.228, pp.228-239, 2014.
DOI : 10.1126/scitranslmed.3007730

G. Tomaras, G. Ferrari, X. Shen, S. Alam, H. Liao et al., Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG, Proceedings of the National Academy of Sciences, vol.110, issue.22, pp.9019-9024, 2013.
DOI : 10.1073/pnas.1301456110

B. Vingert, S. Perez-patrigeon, P. Jeannin, O. Lambotte, F. Boufassa et al., HIV Controller CD4+ T Cells Respond to Minimal Amounts of Gag Antigen Due to High TCR Avidity, PLoS Pathogens, vol.77, issue.2, p.1000780, 20106.
DOI : 10.1371/journal.ppat.1000780.s007

L. Lin, G. Finak, K. Ushey, C. Seshadri, T. Hawn et al., COMPASS identifies T-cell subsets correlated with clinical outcomes, Nature Biotechnology, vol.15, issue.6, pp.610-616, 2015.
DOI : 10.1002/cyto.a.22218

R. De-rose, S. Kent, and C. Ranasinghe, Prime-Boost Vaccination: Impact on the HIV-1 Vaccine Field, Novel Approaches and Strategies for Biologics, Vaccines, and Cancer Therapies, 2014.
DOI : 10.1016/B978-0-12-416603-5.00012-2

J. Skinner, S. Zurawski, C. Sugimoto, H. Vinet-oliphant, P. Vinod et al., Immunologic Characterization of a Rhesus Macaque H1N1 Challenge Model for Candidate Influenza Virus Vaccine Assessment, Clinical and Vaccine Immunology, vol.21, issue.12, pp.1668-1680, 2014.
DOI : 10.1128/CVI.00547-14

O. Epaulard, L. Adam, C. Poux, G. Zurawski, N. Salabert et al., Macrophage- and Neutrophil-Derived TNF-?? Instructs Skin Langerhans Cells To Prime Antiviral Immune Responses, The Journal of Immunology, vol.193, issue.5, pp.2416-2426, 2014.
DOI : 10.4049/jimmunol.1303339

S. Reed, M. Orr, and C. Fox, Key roles of adjuvants in modern vaccines, Nature Medicine, vol.491, issue.12, pp.1597-1608, 2013.
DOI : 10.1074/jbc.M112.347179

C. Vaure and Y. Liu, A Comparative Review of Toll-Like Receptor 4 Expression and Functionality in Different Animal Species, Frontiers in Immunology, vol.114, p.25071777, 2014.
DOI : 10.1016/j.vetimm.2006.09.003

K. Tewari, B. Flynn, S. Boscardin, K. Kastenmueller, A. Salazar et al., Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and ??DEC-CSP in non human primates, Vaccine, vol.28, issue.45, pp.7256-7266, 2010.
DOI : 10.1016/j.vaccine.2010.08.098

H. Park, L. Adamson, T. Ha, K. Mullen, S. Hagen et al., Polyinosinic-Polycytidylic Acid Is the Most Effective TLR Adjuvant for SIV Gag Protein-Induced T Cell Responses In Nonhuman Primates, The Journal of Immunology, vol.190, issue.8, pp.4103-4115, 2013.
DOI : 10.4049/jimmunol.1202958

L. Schneider, A. Schoonderwoerd, M. Moutaftsi, R. Howard, S. Reed et al., Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells, Vaccine, vol.30, issue.28, pp.4216-4224, 2012.
DOI : 10.1016/j.vaccine.2012.04.051

J. Lumsden, S. Pichyangkul, U. Srichairatanakul, K. Yongvanitchit, A. Limsalakpetch et al., Evaluation of the Safety and Immunogenicity in Rhesus Monkeys of a Recombinant Malaria Vaccine for Plasmodium vivax with a Synthetic Toll-Like Receptor 4 Agonist Formulated in an Emulsion, Infection and Immunity, vol.79, issue.9, pp.3492-3500, 2011.
DOI : 10.1128/IAI.05257-11

J. Nkolola, A. Cheung, J. Perry, D. Carter, S. Reed et al., Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer, Vaccine, vol.32, issue.18, pp.2109-2116, 2014.
DOI : 10.1016/j.vaccine.2014.02.001

G. Lewis, Challenges of antibody-mediated protection against HIV-1, Expert Review of Vaccines, vol.9, issue.7, pp.683-687, 2010.
DOI : 10.1586/erv.10.70

J. Mascola and D. Montefiori, The Role of Antibodies in HIV Vaccines, Annual Review of Immunology, vol.28, issue.1, pp.413-444, 2010.
DOI : 10.1146/annurev-immunol-030409-101256

J. Garcia-arriaza, B. Perdiguero, J. Heeney, M. Seaman, D. Montifiori et al., ABSTRACT, Journal of Virology, vol.89, issue.16, pp.8525-8539, 2015.
DOI : 10.1128/JVI.01265-15

A. Flamar, S. Zurawski, F. Scholz, I. Gayet, L. Ni et al., Noncovalent Assembly of Anti-Dendritic Cell Antibodies and Antigens for Evoking Immune Responses In Vitro and In Vivo, The Journal of Immunology, vol.189, issue.5, pp.2645-2655, 2012.
DOI : 10.4049/jimmunol.1102390

A. Flamar, Y. Xue, S. Zurawski, M. Montes, B. King et al., Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells, AIDS, vol.27, issue.13, pp.2041-2051, 2013.
DOI : 10.1097/QAD.0b013e3283624305

K. Kibler, C. Gomez, B. Perdiguero, S. Wong, T. Huynh et al., Improved NYVAC-Based Vaccine Vectors, PLoS ONE, vol.78, issue.11, p.22096477, 2011.
DOI : 10.1371/journal.pone.0025674.g008
URL : http://doi.org/10.1371/journal.pone.0025674

S. White, K. Conwell, J. Langland, and B. Jacobs, Use of a negative selectable marker for rapid selection of recombinant vaccinia virus, Biotechniques, vol.50, pp.303-309, 2011.

D. Montefiori, Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays, Curr Protoc Immunol, vol.280, p.18432938, 2005.
DOI : 10.1002/0471142735.im1211s64

H. Liao, M. Bonsignori, S. Alam, J. Mclellan, G. Tomaras et al., Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2, Immunity, vol.38, issue.1, pp.176-186, 2013.
DOI : 10.1016/j.immuni.2012.11.011

G. Tomaras, N. Yates, P. Liu, L. Qin, G. Fouda et al., Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia, Journal of Virology, vol.82, issue.24, pp.12449-12463, 2008.
DOI : 10.1128/JVI.01708-08

B. Gaschen, J. Taylor, K. Yusim, B. Foley, F. Gao et al., Diversity Considerations in HIV-1 Vaccine Selection, Science, vol.296, issue.5577, pp.2354-2360, 2002.
DOI : 10.1126/science.1070441

H. Liao, L. Sutherland, S. Xia, M. Brock, R. Scearce et al., A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses, Virology, vol.353, issue.2, pp.268-282, 2006.
DOI : 10.1016/j.virol.2006.04.043

M. Donaldson, S. Kao, L. Eslamizar, C. Gee, G. Koopman et al., Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies, Journal of Immunological Methods, vol.386, issue.1-2, pp.10-21, 2012.
DOI : 10.1016/j.jim.2012.08.011

K. Foulds, M. Donaldson, and M. Roederer, OMIP-005: Quality and phenotype of antigen-responsive rhesus macaque T cells, Cytometry Part A, vol.86, issue.5, pp.360-361, 2012.
DOI : 10.1002/cyto.a.22008

J. Pollara, L. Hart, F. Brewer, J. Pickeral, B. Packard et al., High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses, Cytometry Part A, vol.182, issue.8, pp.603-612, 2011.
DOI : 10.1002/cyto.a.21084

J. Pollara, M. Bonsignori, M. Moody, P. Liu, S. Alam et al., ABSTRACT, Journal of Virology, vol.88, issue.14, pp.7715-7726, 2014.
DOI : 10.1128/JVI.00156-14

T. Edmonds, H. Ding, X. Yuan, Q. Wei, K. Smith et al., Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC, Virology, vol.408, issue.1, p.20863545, 2010.
DOI : 10.1016/j.virol.2010.08.028

A. Harari, P. Bart, W. Stohr, G. Tapia, M. Garcia et al., An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses, The Journal of Experimental Medicine, vol.3, issue.1, pp.63-77, 2008.
DOI : 10.4049/jimmunol.173.10.6274
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2234371